Business Parks & Science Centres

 
 
 

Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 5658 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 11 12 13 ... 55 56 57  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Arsanis–Ten Bridge Communications: public relations, 201703 service existent by Ten Bridge 2017-03-01
Avillion–Merck (DE): Nanobody, 201703– collab ww clinical development + regulatory submission of M1095 anti IL-17 A/F Nanobody 2017-03-01
Axolabs–LGC: investment, 201703 acquisition of Axolabs GmbH by LGC 2017-03-01
InfanDx–Arnika Beteiligungen: investment, 201703 investment by new investor Arnika Beteiligungen GmbH 2017-03-01
Omeicos–SEVERAL: investment, 201703 1st closing €8.3m of financing round Series B led by Vesalius Biocapital II 2017-03-01
Addex–SEVERAL: investment, 201702 private placement CHF3m with 1.5m treasury shares at CHF2/share led by Herculis Partners SA 2017-02-28
Sanofi–Lonza: rec protein production, 201703– collab 50/50 jv to establish biologics production facility in CH w initial investment of CHF290 (€270m) 2017-02-27
Adaptimmune–Ally Bridge Group: investment, 201702 existent investment of ABG 2017-02-23
Galenica–Ally Bridge Group: investment, 201702 investment €na by ABG 2017-02-23
Nabriva–Ally Bridge Group: investment, 201702 investment €na by ABG 2017-02-23
Tesaro–Ally Bridge Group: investment, 201702 existent investment of ABG 2017-02-23
WuXi PharmaTech–Ally Bridge Group: investment, 201702 existent investment of ABG 2017-02-23
Neovacs–ActeaVentures: business consulting, 201702 supply service business development advisor for Neovacs license deal w BioSense Global LLC 2017-02-21
Bayer–Yara: digital farming, 201702– collab + license ww to ImageIT mobile imaging technology for plant monitoring + farming recommendations 2017-02-20
Oncgnostics–Thuringia (govt): investment, 201702 additional investment of €500k from bm|t 2017-02-20
Univ Warwick–Bruker Corp: NMR spectrometer, 201702 supply existent of Bruker 850 WB US² system at NMR Facility 2017-02-17
BioMedPartners–SEVERAL: investment, 201702 first closing CHF75m of BioMedInvest III fund incl cornerstone investor EIF + Berner Kantonalbank 2017-02-16
Selecta Biosciences–Lonza: gene therapy products, 201702– supply contract manufacturing of Anc80-AAV-based gene therapy product by Lonza Houston Inc 2017-02-16
Boehringer–Cornell Univ: drug discovery, 201702– collab 3y identify COPD treatm approaches Weill Cornell Medicine Dept of Genetic Medicine 2017-02-15
Boehringer–Inventiva: pharmaceutical, 201702 collab r+d existent 2017-02-15
Jecure Therapeutics–Versant Ventures: investment, 201702 financing round Series A $20m from founding investor Versant Ventures 2017-02-15
Immunicum–MacDougall Biomedical Communications: public relations, 201702 service existent by MacDougall 2017-02-13
Santhera–SEVERAL: credit, 201702–202202 senior unsecured convertible bonds CHF60m 5% due 202202 2017-02-10
Evotec–Novo Group: investment, 201702 strategic investment of €90.3m 13.15m new Evotec shares at €6.87/share resulting in 8.9% ownership by Novo A/S 2017-02-09
NewLink Genetics–Cevec: rec protein production technology, 201702– license €na to CAP GT + CAP Go cell lines for Zika vaccine developm + commerc 2017-02-09
Albany Molecular–Bruker Corp: mass spectrometer, 201702 supply MALDI PharmaPulse system to AMRI by Bruker Daltonics + HighRes Biosolutions 2017-02-07
Atriva Therapeutics–High-Tech Gründerfonds: investment, 201702 seed financing round led by Stichting Participatie Atriva + HTGF 2017-02-07
Atriva Therapeutics–SEVERAL: investment, 201702 seed financing round led by Stichting Participatie Atriva + HTGF plus private investors 2017-02-07
Atriva Therapeutics–Stichting Participatie Atriva: investment, 201702 seed financing round led by SPA + HTGF 2017-02-07
Bruker Corp–Albany Molecular: mass spectrometry, 201702– collab developm of HTS applications using MALDI PharmaPulse system from Bruker + HighRes 2017-02-07
Labor Limbach–Numares: NMR-based IVD tests, 201702 collab existent Labor Limbach offers IVD test LipoComplete 2017-02-07
Prexton Therapeutics–Forbion: investment, 201702 financing round Series B totalling €29m co-led by new investors Forbion + Seroba 2017-02-07
Prexton Therapeutics–Merck (DE): investment, 201702 financing round Series B totalling €29m incl returning co-investor Merck Ventures 2017-02-07
Prexton Therapeutics–Seroba: investment, 201702 financing round Series B totalling €29m co-led by new investors Forbion + Seroba 2017-02-07
Prexton Therapeutics–SEVERAL: investment, 201702 financing round Series B €29m co-led by new investors Forbion + Seroba 2017-02-07
Prexton Therapeutics–Sunstone Capital: investment, 201702 financing round Series B totalling €29m incl returning co-investor Sunstone Capital 2017-02-07
Prexton Therapeutics–Ysios Capital: investment, 201702 financing round Series B totalling €29m incl returning co-investor Ysios Capital 2017-02-07
Bruker Corp–Endress+Hauser: mass spec sample preparation, 201702 collab Analytik Jena uHTS MALDI sample prep for rapifleX MALDI Pharma Pulse MS 2017-02-06
GSK–Bruker Corp: mass spectrometer, 201702 supply existent MALDI PharmaPulse 2.0 incl rapifleX MALDI-TOF System at GSK Platform Tech + Science group 2017-02-06
Wilex–Hopp Group: investment, 201702– financing commitment of up to €10m by Dievini Hopp [not announced whether credit or investment] 2017-02-06
Coral BioNet–UV-Cap: investment, 201702 acquisition 100% of Scil Proteins GmbH from Bionet Ventures GmbH by UV-Cap GmbH & Co KG 2017-02-03
Leukocare–Rentschler: investment, 201702 acquisition of 10% stake in Leukocare AG by Rentschler Biotechnologie GmbH as part of strategic alliance 2017-02-02
Ottobock–Steeper: prosthetic, 201702 acquisition of BeBionic hand product range by Ottobock from Steeper 2017-02-02
Rentschler–Leukocare: drug formulation technology, 201702– collab strategic alliance using SPS technology for biopharmaceuticals 2017-02-02
Immunic–Saxony-Anhalt (govt): investment, 201702 investment Series A €4m by new investor IBG bringing total to €21.7m 2017-02-01
Lonza–SEVERAL: investment, 201701–201702 capital increase CHF865m placing 5m new shares at CHF173/share to selected/qualified investors 2017-01-31
Regeneron–Indivumed: tissue banking, 201701– collab + supply €na tissue samples w clinical + molecular data for cancer research 2017-01-31
Medizinsches Labor Bremen–Sonic Healthcare: investment, 201701– acquisition for €63m (cash + debt free) of MLB by Sonic Healthcare Ltd 2017-01-30
ProteomeTools project–BioNTech: proteomics, 201701 collab existent JPM Peptide Technologies is project partner 2017-01-30
ProteomeTools project–SAP: proteomics, 201701 collab existent SAP is project partner 2017-01-30
ProteomeTools project–Thermo Fisher: proteomics, 201701 collab existent Thermo Fisher Scientific is project partner 2017-01-30
ProteomeTools project–TU Munich: proteomics, 201701 collab existent TUM is coordinating project partner in developing PROPEL library 2017-01-30
SGS–SEVERAL: credit, 201701–202601 nine year CHF375m straight bond with coupon of 0.55% 2017-01-30
Sonic Healthcare–McDermott Will & Emery: legal services, 201701 advisor for acquisition of Medical Lab Bremen by Sonic Healthcare Ltd 2017-01-30
United Kingdom (govt)–Qiagen: genomic database, 201701– Genomics England to use HGMD Online Professsional solution for 100,000 Genomes Project 2017-01-30
Actelion–JnJ: investment, 201701–201706 acquisition $30b all-cash tender offer funded w JnJ cash held outside of US 2017-01-26
Cellestia Biotech–PPF Group: investment, 201701 seed financing round Series C totalling CHF5.2m incl Sotio/PPF Group + private investors 2017-01-26
Actelion–Enamine: chemical compound library, 201701– collab expansion supply of screening compound library to Actelion 2017-01-23
Merck (DE)–Domain Therapeutics: cancer drugs, 201701– collab developm + ww license to adenosine receptor antagonists 2017-01-23
Affimed–SEVERAL: investment, 201701 public offering $18m + $2.7m with 10m+1.5m common shares at $1.8/share 2017-01-19
Asahi Kasei–Evotec: drug discovery, 201701– supply service €na expansion into integrated drug discovery collab for inhibitors of ion channel targets 2017-01-19
Fibrocor Therapeutics–Evotec: drug discovery services, 201701– collab developm fibrosis drugs w all drug discovery activities done by Evotec 2017-01-17
Fibrocor Therapeutics–Evotec: investment, 201701 Evotec to receive equity stake in Fibrocor as part of collaboration 2017-01-17
Fibrocor Therapeutics–SEVERAL: investment, 201701 seed financing C$2.8m ($2.1m) incl cash from co-founder MaRS Innovation 2017-01-17
Mologen–SEVERAL: credit, 201701–202501 convertible bonds €4.99m at 6% incl major shareholder GTD 2017-01-17
Northwell Health–Indivumed: tissue bank, 201701– collab to create cancer research biobank 2017-01-17
Luxendo–Huntsworth: public relations, 201701 service existent by Citigate Dewe Rogerson 2017-01-12
Luxendo–SEVERAL: investment, 201701 financing round Series A extension €2m bringing total to €8m co-led by LSP + EMBL Ventuers + EMBLEM 2017-01-12
Crescendo Biologics–Genedata: bioinformatics, 201701– license to Genedata Biologics as workflow platform for internal + partnered Humabody programs 2017-01-10
Amgen–Immatics: cancer immunotherapy, 201701– strategic collab $30m upfront + $500m milestones + royalties combining Xpresident + BiTE technologies 2017-01-09
Arrowhead–Silence Therapeutics: investment, 201701 acquisition 6.83m common shares = 9.21% shareholding for $11.3m 2017-01-09
Epidarex Capital–Lilly: investment, 201701 existent one of several investors in Epidarex is Eli Lilly 2017-01-09
Eternygen–Berlin (govt): investment, 201701 financing round Series A totalling €8m incl co-investor VC Fonds Technologie managed by IBB 2017-01-09
Eternygen–Epidarex Capital: investment, 201701 financing round Series A totalling €8m incl lead investor Epidarex Capital 2017-01-09
Eternygen–Evotec: investment, 201701 financing round Series A totalling €8m incl co-investor Evotec AG 2017-01-09
Eternygen–MC Services: public relations, 201701 service existent by MC Services AG 2017-01-09
Eternygen–SEVERAL: investment, 201701 financing round Series A €8m led by Epidarex Capital plus Evotec + VC Fonds Technologie + 2 family offices et al 2017-01-09
Merck (DE)–Univ Texas: oncology, 201701–201912 strategic collab using MD Anderson’s APOLLO platform for cancer drug development 2017-01-09
OmicSoft–Qiagen: investment, 201701 acquisition €na of OmicSoft by Qiagen 2017-01-09
Servier–McDermott Will & Emery: legal services, 201701 advisor immuno-oncology co-developm agreem of Servier with Pieris Pharmaceuticals 2017-01-09
Anokion–Celgene: investment, 201701 acquisition of equity interest by Celgene as part of research collab research plus excl option to acquire Anokion 2017-01-08
Celgene–Anokion: immune tolerance inducing drugs, 201701– collab research $45m upfront + $10m milestones + equity share + right to acquire Anokion 2017-01-08
HepaRegenix–Boehringer: investment, 201701 financing round Series A totalling €9m co-led by BIVF + Novo Seeds + incl HTGF + Coparion 2017-01-05
HepaRegenix–Germany (govt): investment, 201701 financing round Series A totalling €9m co-led by BIVF + Novo Seeds + incl HTGF + Coparion 2017-01-05
HepaRegenix–High-Tech Gründerfonds: investment, 201701 financing round Series A totalling €9m co-led by BIVF + Novo Seeds + incl HTGF + Coparion 2017-01-05
HepaRegenix–MC Services: public relations, 201701 service existent by MC Services AG 2017-01-05
HepaRegenix–Novo Group: investment, 201701 financing round Series A totalling €9m co-led by BIVF + Novo Seeds + incl HTGF + Coparion 2017-01-05
HepaRegenix–SEVERAL: investment, 201701 financing round Series A €9m co-led by BIVF + Novo Seeds + incl HTGF + Coparion 2017-01-05
Merck (US)–Valneva: cell line, 201701– research license €na for development of new vaccines using EB66 technology to MSD Animal Health 2017-01-05
Servier–Pieris: cancer immunotherapy, 201701– collab €30m upfront + milestones to develop bi-specific ABs using Anticalin technology incl PRS-322 2017-01-05
Xigen–Instinctif Partners: public relations, 201701 service existent by Instinctif Partners 2017-01-05
Affimed–Univ Texas: cancer immunotherapy, 201701– collab clinical + commerc to evalaute TandAbs with natural killer cell product of MD Anderson 2017-01-04
Aptarion Biotech–Noxxon: investment, 201701 Noxxon receives Aptarion shares as part of transfer of preclinical assets to Aptarion 2017-01-04
Aptarion Biotech–Noxxon: Spiegelmer technology, 201701 acquisition techn + preclinical assets + lab assets from Noxxon for cash + royalties + shares 2017-01-04
BioControl Systems–Merck (DE): investment, 201701 acquisition €na of BioControl Systems Inc by Merck KGaA 2017-01-04
InVivo Biotech Services–Bruker Corp: investment, 201701 acquisition €na of InVivo Biotech Services GmbH by Bruker 2017-01-04
SCiLS GmbH–Bruker Corp: investment, 201701 acquisition €na of SCiLS GmbH by Bruker 2017-01-04
Tiziana–Novimmune: therapeutic antibody, 201701– license excl €na to develop + commercialise anti-IL-6R MAb NI-1201 2017-01-04
Laboratoire LCA (MA)–SGS: investment, 201701 acqisition by SGS 2017-01-03
Bio-ITech–Eppendorf: investment, 2017Q1 acquisition of majority share in Bio-ITech BV by Eppendorf 2017-01-01
next pagenext page 1 2 3 ... 11 12 13 ... 55 56 57  next pagenext page



Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

» top